PharmaCyte Biotech, Inc.
PMCBHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframePart of the healthcare sector, PharmaCyte Biotech, Inc. (PMCB) is listed under Biotechnology. With a market capitalization of $5.2M, it sits in micro-cap territory. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer.
Market Cap
$5.2M
Beta
0.66
P/E (TTM)
—
P/E (Fwd)
-1.28
EPS (TTM)
$-2.77
EPS (Fwd)
$-0.38
ROE
-44.7%
ROA
-6.5%
Cash
$37.1M
Total Debt
$0
Free CF
$2.2M
52W Change
-54.4%
Annual Financials
Cash vs Debt
Where PMCB stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PMCB finished 31.43% below its 150-day moving average ($0.70) and 35.14% below its 200-day moving average ($0.74). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PMCB overbought or oversold?
At the September 3, 2026 close, PMCB's RSI(14) was 27.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
PharmaCyte Biotech, Inc. reports $37.1M in cash and $0 in total debt. Annual free cash flow of $2.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -44.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, PharmaCyte Biotech, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. No single metric tells the full story. Reviewing PMCB's risk profile alongside its fundamentals and technical indicators provides a more complete picture.